Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
about
Targeted therapies in sarcomas: challenging the challengeNilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasLigand-target prediction by structural network biology using nAnnoLyzeEffects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.New therapeutic targets in soft tissue sarcoma.Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.Emerging therapeutic targets for synovial sarcoma.SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.Multimodality therapy for metastatic sarcomas confined to the lung.Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluationHuman interleukin 23 receptor induces cell apoptosis in mammalian cells by intrinsic mitochondrial pathway associated with the down-regulation of RAS/mitogen-activated protein kinase and signal transducers and activators of transcription factor 3 siTargeting mitogen-activated protein kinase kinase (MEK) in solid tumors.Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.Past, present and future of therapies in pediatric sarcomas.Antiangiogenic approach in soft-tissue sarcomas.Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.Targeted polytherapy in small cell sarcoma and its association with doxorubicin.Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging.Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.The molecular biology of soft-tissue sarcomas and current trends in therapy.(-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells.Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells.Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
P2860
Q21285014-AA25649D-38E3-4C66-ABB4-44D2EC838007Q28483929-6AE27D40-AAA3-4070-9A0E-10F32A97551FQ28545126-DED2805B-9560-45D4-8524-C5896BB5148DQ28732214-554412BE-B52A-49C3-A290-E7E816B897B4Q33404411-8BD813E0-312F-49DE-9BA1-56E59A4AB739Q33408668-E9FF4C70-4D50-46D0-9180-391DE6FFDFB9Q34267924-441332D7-45F6-4500-AF9B-146E37B31C29Q34653360-6C18BB90-BC57-46A3-A6A0-E7B2F664ACBDQ34660607-CF028C26-45AF-4F32-93BF-526F233552E9Q35200425-09F927E5-EFC1-4F6D-9EF8-69AB1AE90331Q36424138-8B934C36-4D47-4254-BEF5-DDE769C391C1Q37061029-81E006CB-4C0F-4BCA-8709-1F216BB539B9Q37150456-88138A19-20B5-4089-9126-3F506C4D8FD8Q37187778-FCC881BB-5F3A-4E57-8D55-E06B8263F676Q37222595-8BF232A6-0E74-4347-9FAD-B1605960F3E8Q37421049-A3692A19-8140-4BBC-BEC2-55637920DA68Q37629722-F0522903-1B65-4CB3-BC86-CE190BFC0A59Q37687079-B9983F80-CBAC-4A33-864C-E528887125BFQ37725915-7CA97706-A02E-4C40-9E2F-BE0D52F977F4Q38128896-F5830405-E2C1-4274-B523-91A439E68AF8Q38712735-A8F3E62F-591A-475E-AF95-4741B9E2976AQ38977714-4EA848C9-EA2D-4D61-BEC1-8DDB64B48925Q39162638-0344536A-E3ED-4092-84E6-7C7D97329E60Q39184863-F6A33882-846C-47D8-9C11-6DA488543C06Q39592084-957B7806-7E12-471D-835A-900DE8B72C70Q39660386-4FD8A6C6-43EE-4EF0-B073-867371108140Q42177224-160E9458-D7E7-4741-82AD-CCA4835CF0F0Q43176386-3FC9C0D1-CFF4-4ED7-9932-19CBE3E7A00EQ52649674-E504292D-F8A8-49F2-ACBF-C4D03E0D5521Q53082217-42366C64-C5F1-4F89-96D8-568A42EF6909
P2860
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway.
@en
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway.
@nl
type
label
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway.
@en
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway.
@nl
prefLabel
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway.
@en
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway.
@nl
P2093
P356
P1476
Sorafenib induces growth inhib ...... RAF/MEK/ERK signaling pathway
@en
P2093
Chang-Liang Peng
Tai-Qiang Yan
Tingting Ren
Xiao-Dong Tang
P304
P356
10.4161/CBT.8.18.9208
P50
P577
2009-09-06T00:00:00Z